Dr Andrew Shuttleworth joins NanoSight board as Director of Diagnostic Sciences

June 26, 2012
Salisbury, United Kingdom -- Manufacturer of nanoparticle characterization technology, NanoSight, has announced the appointment of renowned UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director of Diagnostic Sciences.

Salisbury, United Kingdom -- Manufacturers of nanoparticle characterization technology, NanoSight, has announced the appointment of renowned UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director of Diagnostic Sciences. Dr Shuttleworth's appointment further strengthens the scientific team. His experience will greatly add to NanoSight's position as the UK's fastest growing Biotechnology company.

Andrew Shuttleworth brings a wealth of scientific knowledge to NanoSight's rapidly expanding organization. Having been awarded degrees in applied biological sciences and virology, he spent twenty years at Porton Down research establishments involved in both fundamental research in microbiology and immunology, and the application of that research to medical and defense issues; particularly the rapid identification of select biological agents. This led to a leading role in the development of the UK's first practical biological agent detection system, fielded during the Gulf War in 1991, and acted as the scientific liaison on chemical and biological issues with UK and US Forces throughout the Gulf region. Andrew returned to Porton Down where he directed a team of analytical chemists, microbiologists and operational analysts providing chemical and biological risk and threat assessments. He also provided real-time operational advice and support to the Ministry of Defence, the Home Office and other government departments. In 2001, Andrew took up an appointment with the UK Foreign & Commonwealth Office to provide scientific advice and expertise on a diverse range of topics of national interest.

Andrew Shuttleworth comments: "The emerging field of exosomes and nanovesicles now looks set to give rise to a fundamental shift in the way in which disease is detected, diagnosed and monitored. Currently, it is a growing research field, which NanoSight is exploiting fully through the provision of increasingly capable research instrumentation. Eventually, multiple biomarkers will be identified for each relevant disease state and this will drive the development of new analytical capabilities. Whilst it is too early to suggest that NanoSight technology will supplant existing capabilities (e.g. ELISA, qPCR), it would be prudent to recognize that NanoSight has the potential to do so – particularly where multiple-parameter tests and quantitative results might be desirable. NanoSight also has the potential to assist in the development of other novel assay systems that might be needed to fully exploit the potential benefits of exosomes and nanovesicles."

-----

Follow us on Twitter and 'like' us on Facebook

Follow OptoIQ on your iPhone; download the free app here.

About the Author

Kellie Chadwick | Editorial Intern

Sponsored Recommendations

March 31, 2025
Enhance your remote sensing capabilities with Chroma's precision-engineered optical filters, designed for applications such as environmental monitoring, geospatial mapping, and...
March 31, 2025
Designed for compatibility with a wide range of systems, Chroma's UV filters are engineered to feature high transmission, superior out-of-band blocking, steep edge transitions...
March 31, 2025
Discover strategies to balance component performance and system design, reducing development time and costs while maximizing efficiency.
March 31, 2025
Filter accessories including cubes, sliders, and rings, designed to enhance the performance and versatility of optical systems. These components ensure precise alignment and stability...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!